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Background: The transcription factor p63 belongs to the p53/p63/p73 family and plays key functional roles during
normal epithelial development and differentiation and in pathological states such as squamous cell carcinomas. The
human TP63 gene, located on chromosome 3q28 is driven by two promoters that generate the full-length transactivating
(TA) and N-terminal truncated (ΔN) isoforms. Furthermore alternative splicing at the C-terminus gives rise to additional α,
β, γ and likely several other minor variants. Teasing out the expression and biological function of each p63 variant has
been both the focus of, and a cause for contention in the p63 field.
Results: Here we have taken advantage of a burgeoning RNA-Seq based genomic data-sets to examine the global
expression profiles of p63 isoforms across commonly utilized human cell-lines and major tissues and organs. Consistent
with earlier studies, we find ΔNp63 transcripts, primarily that of the ΔNp63α isoforms, to be expressed in most cells of
epithelial origin such as those of skin and oral tissues, mammary glands and squamous cell carcinomas. In contrast, TAp63
is not expressed in the majority of normal cell-types and tissues; rather it is selectively expressed at moderate to high
levels in a subset of Burkitt’s and diffuse large B-cell lymphoma cell lines. We verify this differential expression pattern of
p63 isoforms by Western blot analysis, using newly developed ΔN and TA specific antibodies. Furthermore using
unsupervised clustering of human cell lines, tissues and organs, we show that ΔNp63 and TAp63 driven transcriptional
networks involve very distinct sets of molecular players, which may underlie their different biological functions.
Conclusions: In this study we report comprehensive and global expression profiles of p63 isoforms and their
relationship to p53/p73 and other potential transcriptional co-regulators. We curate publicly available data
generated in part by consortiums such as ENCODE, FANTOM and Human Protein Atlas to delineate the vastly
different transcriptomic landscapes of ΔNp63 and TAp63. Our studies help not only in dispelling prevailing myths
and controversies on p63 expression in commonly used human cell lines but also augur new isoform- and cell
type-specific activities of p63.
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The transcriptional networks that govern temporally and
spatially regulated gene expression programs are remark-
ably dynamic and complex [1]. One major factor that
bestows this complexity is the incredible diversity of
Transcription Factor (TF) isoforms that frequently arise
from molecular events such as alternative splicing and
promoter usage [2]. These isoforms, representing different
protein products from the same gene, have distinct bio-
logical properties and thus can shape the transcriptional
landscape of any cell in unique fashion. Hence any func-
tional and deterministic studies of TFs should begin with
careful parsing of the expression levels of its various iso-
forms across a wide-range of cell and tissue types. In the
past, lack of large-scale expression data sets and appropri-
ate tools such as isoform-specific antibodies have often
hampered such studies and led to confusion and contra-
dictory findings. This is quite evident in the case of the
p53/p63/p73 family of proteins and is particularly true for
p63 [3–6].
p63 is a developmentally important transcription fac-
tor involved in orchestrating a wide-ranging repertoire
of biological functions such as cell fate determination,
stem cell renewal, apoptosis and differentiation amongst
others [7–12]. What complicates our understanding of
p63 is that like other members of the p53 family, it is a
structurally complex gene that generates multiple iso-
forms [7]. Thus the human TP63 gene encodes for full-
length transactivating (TA) and N-terminal truncated
(ΔN) isoforms resulting from the usage of an upstream
and an alternate intronic promoter, respectively. In
addition, both TAp63 and ΔΝp63 transcripts undergo al-
ternative splicing at the 3’ end resulting in at least three
major C-terminal protein variants, termed α, β, and γ.
These p63 isoforms share significant structural and func-
tional homologies with p53 and p73 in the DNA-binding
domain, which exhibit conservation of all essential DNA
contact amino acid residues [13]. This similarity also ex-
tends to the transactivation and oliogomerization domains
[3, 14]. In contrast, the α isoforms are unique to p63 and
p73 in that they contain the sterile alpha motif (SAM) do-
main, which can act as a docking station for the formation
of large protein complexes and a transcription inhibitory
domain (TID). Not surprisingly, the complexities of the
p63 isoforms weave a complicated functional interplay be-
tween themselves as well as within the extended network
of the other two family members.
During the past several years, a number of experimen-
tal discoveries, driven primarily by the availability of
isoform-specific knock out mouse models have been of
immense value in improving our understanding of the
physiological as well as pathological functions of p63
isoforms [15–20]. These studies have firmly established
that ΔΝp63, in particular the ΔΝp63α isoforms are thepredominant [21, 22] and most widely distributed pro-
teins in many epithelial rich mouse tissues and organs
and consequently are of the utmost functional relevance
in vivo. Indeed, the bulk of the developmental role of
p63 is shouldered by the ΔΝp63 isoforms. This is clearly
evident in the phenotype of the ΔNp63-null animals,
which show widespread defects of the skin, oral epithe-
lium, mammary glands, limb and craniofacial regions—a
developmental block that is quite similar to what has been
reported for mice that lack all p63 isoforms [17–19, 23].
The specific role of TAp63 on the other hand has been
mired in controversy, in part due to the conflicting and
often unsubstantiated reports of its expression pattern
under normal physiological conditions and its complex
role in cancer [22, 24–26]. However, recent TAp63 specific
knockouts have begun to shed some light and have re-
vealed that this isoform plays only a minor role, if any,
during normal epithelial development. The emerging evi-
dence also suggests that TAp63 is induced in response to
stress and under specific conditions, contributes to the
maintenance of adult skin stem cells, serves as robust me-
diators of senescence and as regulators of lipid and glu-
cose metabolism [16, 27].
The disparate role of p63 isoforms also extends to vari-
ous types of human tumors, where there is aberrant ex-
pression of TAp63 and ΔNp63. In general the current
consensus is that the ΔNp63 proteins act as oncogenes by
antagonizing p53 and through other alternate p53-
indepedent mechanisms, while TAp63 isoforms are tumor
and metastatic suppressors—an observation supported by
mouse models [20, 28–31]. However, results of studies
from human tumors paints a complicated picture, with
contradictory views in terms of the levels of expression of
various p63 isoforms and its relation to clinical outcomes
[28]. One major reason for such discrepancy is the fact
that the p63 antibodies utilized in such studies do not dis-
tinguish between the TA and the ΔN isoforms. Moreover,
these antibodies have been shown to cross-react with p73
[32]. Thus there is a dire need to carefully and methodic-
ally examine the expression profile of the various p63 iso-
forms, particularly in commonly used human cell lines,
which over the years have been heavily exploited to test
p63 function. With the advent of next generation sequen-
cing techniques (such as RNA-Seq) and ever-increasing
genomic datasets, it is now feasible to re-evaluate the p63
status in a global fashion.
Here, we have generated RNA-Seq datasets for several
important HNSCC cell-lines, combined them with avail-
able datasets from the literature and the ENCODE project
[33] to determine the expression profile of p63 isoforms.
Our data reinforces the notion that ΔNp63 and TAp63
have very different expression patterns across a large num-
ber of human cell lines and tissues. In particular, we show
that ΔNp63 mRNA is highly prevalent in epithelial cells
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versely, TAp63 expression is largely absent from com-
monly used cell lines, including a few that have been
referenced in the literature and which have been utilized
for TAp63-specific studies. Rather, we find that TAp63 is
selectively expressed in B lymphoma cell lines. Import-
antly, we have confirmed our results by western blot ana-
lysis of a subset of selected human cell lines using newly
developed ΔN/TA specific antibodies. Finally, we utilize
unsupervised clustering analysis to generate network
maps, which reveal distinct transcriptional co-regulators
for ΔNp63 and TAp63, implying very different functional
roles for the p63 isoforms.Results and discussion
Transcriptomic map of human cells derived from existing
and newly generated RNA-Seq datasets
With the increasing availability of expression data sets
for a large number of human cell lines, it is possible to
determine the expression profile of each p63 variant at a
global level. Therefore, we mined publicly available
RNA-Seq databases generated by the ENCODE project
and existing literature to obtain transcriptomic maps of
34 commonly used and well characterized human cell
types (Additional file 1: Table S1). Importantly, we chose
representative human cells that corresponded to the
three germ layers in terms of their likely developmental
origins and also included primary, immortalized and
tumor-derived types. In our search for suitable squa-
mous cell carcinoma (SCC) cell lines for p63-centric
studies, it was apparent that RNA-Seq expression pro-
files of SCCs were somewhat limited in the public do-
main. Given that p63 overexpression and/or genomic
amplification is commonly observed in SCCs of the lung,
esophagus and head and neck [28], we performed our
own RNA-Seq based expression profiling of six SCC cell
lines. These SCC cell types are different in both anatom-
ical sites of origin and tumor grade (Additional file 1:
Table S1). To ensure that the datasets were robust and
not encumbered by shortcomings or limitations of any
given computational method, the raw sequencing signal
reads from these 40 human cell types were independ-
ently processed through two well-established RNA-Seq
pipelines [34, 35] (see Methods). The gene expression
estimates measured in fragments per kilobase of tran-
script per million (FPKM) obtained from the two differ-
ent methods were highly concordant as evident by both
similar FPKM values of TFs across individual cell-types
and high correlation (median r = 0.9) across all cell-
types (Additional file 2: Figure S1). For downstream
analysis we utilized Analysis Pipeline 1 as our primary
method to perform systematic examination and com-
parison of comprehensive gene expression patterns.TAp63 and ΔNp63 have distinct, non-overlapping
expression patterns
The TP63 gene generates full-length transactivating TA iso-
forms from an upstream promoter whereas an intronic
promoter regulates the expression of the truncated ΔN
transcripts (Fig. 1a, b). Using the transcriptomic profiles of
the 40 human cell-types, we determined the relative distri-
bution of TAp63 and ΔNp63 transcripts. Consistent with
what has been previously reported in the literature, ΔNp63
transcripts were abundantly detected in keratinocytes de-
rived from skin (NHEK and DK), oral tissue (OKF6) and
primary (HMEC and HMEpC) as well as immortalized
(MCF10A) epithelial cells derived from the mammary
gland. In addition, ΔNp63 was also highly expressed in a
wide range of squamous cell carcinomas (5 out of the 6
HNSCC cell-lines that were examined) (Fig. 1c, Additional
file 3: Table S2). In contrast, the commonly used breast
cancer cell lines expressed extremely low (less than five
FPKM in MCF7) or undetectable (T47D, MDA-MB436
and MDA-MB231) levels of ΔNp63 (Additional file 3:
Table S2). This result was surprising given that these
commonly utilized breast cancer cell lines have served
as valuable models for biochemical experiments to
examine p63 function, as reported in several published
studies [36–38]. Our analysis of the RNA-Seq data set also
revealed that ΔNp63 transcripts were not detectable in a
large number of cell types that represented non-epithelial
developmental origins such as Normal Human Epidermal
Melanocytes (NHEM), Normal Human lung fibroblasts
(NHLF) or commonly used hematopoietic cancer cell lines
(K562 or RAJI) (Additional file 3: Table S2).
Unlike ΔNp63, TAp63 expression levels were quite
low across a wide spectrum of the cell lines examined.
Indeed, a majority of the ΔNp63+ve cell lines did not co-
express TAp63 transcripts, although a few of the SCC cell
lines and MCF7 showed very low levels of TAp63 mRNA
expression. We also found that TAp63 was expressed at
low levels in A549 cells, a human lung adenocarcinoma
derived epithelial cell line, while the commonly used non-
small cell lung cancer (NSCLC) cell line, H1299 did not
express TAp63 (Additional file 3: Table S2). The lack of
any TAp63 expression in H1299 as revealed by our ana-
lysis of the RNA-Seq data is particularly troubling given
that there are published functional studies on endogenous
TAp63 in this cell line [39, 40]. On the other hand, the
RNA-Seq data fits well with an opposing view from other
laboratories, which have primarily used the H1299 cell line
as a p63-null model system to examine the consequences
of addition of exogenous p63 [32, 41]. Among the likely
explanations for this discordant result are mistaken cell
identity or differences in specific growth conditions for
H1299 cells. These conflicting results highlight the im-
portance of careful evaluation of p63 expression levels by
deep sequencing and when possible, verification of the
Fig 1 RNA-Seq reveals distinct expression patterns for TAp63 and ΔNp63. a Cartoon depicting ΔNP63 (α, β, γ) and TAp63α gene structure. TA β
and γ (not shown) undergo similar alternative splicing to ΔNP63 (β, γ). TA, transactivation; Oligo, oligomerization; SAM, sterile alpha motif; TID,
transactivation-inhibitory domain; UTR, untranslated region. b Snapshot from UCSC genome browser showing distribution of the aligned RNA-Seq
reads at the TP63 locus in representative epithelial cell-lines (Head and neck squamous cell carcinoma (SCC) cell-lines: SCC4 and SCC15) and
Non-Hodgkin lymphomas (Burkitt lymphoma cell-lines: Raji and BL2). c Heatmap depicting the expression of p63 isoforms (average across
replicates) in FPKM (fragments per kilobase of transcript per million) across representative p63 expressing cell-lines
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such as quantitative RT-PCR (qRT-PCR) before choosing
the appropriate cell line for studies on p63. Towards this
end, we examined representative TAp63 and ΔNp63 ex-
pressing cell lines and performed isoform-specific qRT-
PCR (Additional file 4: Figure S2). Our studies revealed
that at least in these selected cell lines, the qRT-PCR based
expression pattern of the N-terminal variants of p63
matched quite well with the corresponding data from
RNA-Seq experiments, although the range of expression
was noticeably pronounced as can be expected from the
higher sensitivity of the PCR based approach.Interestingly, instead of epithelial cell lines, TAp63 ex-
hibited a wide range of expression levels in Burkitts
Lymphomas (BL) cell-lines, with relatively strong in a
few (BL2, GUMBUS, FARAGE, BL30), moderate to low
in others (RAJI and DAUDI) and undetectable in an-
other subset (BL70 and RAMOS for e.g.). Low levels of
TAp63 were also observed in GM12878, a lymphoblas-
toid ENCODE Tier one cell line that has served as a
workhorse for many of the genomic projects (Fig. 1c).
Collectively our analysis revealed a complex expression
pattern for the two major p63 isoforms and established
that TAp63 and ΔNp63 have very different expression
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mal lineage, whereas TAp63 is mostly restricted to cells
of mesodermal origin.
One major caveat to the RNA-Seq based expression
analysis is that it often exemplifies only a snapshot of a
specific state of the cells. Furthermore, the data can be
heavily skewed by various extraneous factors such as cell
passage number, growth conditions and state of con-
fluency among others. Thus it is likely that the final ver-
dict on the expression (or lack there of) of p63 isoforms
in a particular cell type will require comprehensive ex-
periments that cover a wide range of physiological con-
ditions. A case in point is the differentiation program of
keratinocytes, which can be well mimicked in cell cul-
ture conditions. One prevailing notion in the field is that
while ΔNp63 are the predominant isoforms in basal pro-
liferating keratinocytes, differentiation of the keratino-
cytes is accompanied by a switch from ΔNp63 to TAp63
[42, 43]. To test this hypothesis, we examined RNA-Seq
data obtained from human keratinocytes at different
time points (DK0, DK3 and DK6) of the differentiation
program [44]. This analysis showed that although there
was a significant diminution in the expression levels of
ΔNp63 transcripts with differentiation, surprisingly under
no conditions was TAp63 expression detected (Additional
file 5: Figure S3)—a finding that corroborates well with
the results of RNA polymerase II ChIP experiments on
the p63 TA and ΔN promoters [45].
Another factor that can influence the outcome of RNA-
Seq based transcriptomic studies is the depth of sequen-
cing coverage [46]. Indeed biological samples often have
different numbers of transcribed genes/transcripts, differ-
ent degree of transcriptome complexity and a dynamic
distribution of expression levels for transcripts–all of
which can make data interpretation quite challenging.
Hence, it is possible that some of the p63 isoform expres-
sion data derived from the RNA-Seq experiments as de-
scribed here, could in part be tinged with effects from
over or under sequencing and thus might not be com-
pletely accurate in the biological context. We have tried to
minimize this limitation by ensuring that most of the sam-
ples that were included were sequenced to a reasonable
depth and wherever possible, replicates were analyzed. A
complementary approach to test if a specific gene is in-
deed expressed or silent in a particular cell type is to probe
chromatin accessibility data such as those generated from
DNase-Seq experiments [47]. Hence, we examined the
chromatin architecture of the two primary p63 promoters
across three disparate cell types–human epidermal kerati-
nocytes (NHEK), B cells (GM12878) and mammary
adenocarcinoma (MCF7) for which DNase-Seq data was
publicly available. As shown in Additional file 6: Figure S4,
NHEK cells showed a clear DNase hypersensitive mark se-
lectively at the ΔNp63 promoter but not at the TAp63promoter whereas GM12878 cells displayed a diametric-
ally opposite pattern. Therefore this data would suggest
that the ΔN and TA promoters are open and active in ker-
atinocytes and GM12878 respectively, in good agreement
with the expression data from RNA-Seq. Interestingly, ac-
cording to the DNase-Seq data, both the TA and ΔN pro-
moters were inaccessible in MCF7 cells–this may very
well account for the very low levels of TAp63 and ΔNp63
transcripts in this cell type.
Relative abundance of the alternatively spliced isoforms
of p63
Although RNA-Seq has rapidly become the method of
choice for global transcriptomic studies, proper assem-
bly, identification and expression quantification of gene
transcripts remains a challenging process that is heavily
dependent both on the computational software and the
reference transcript annotation file used for genome-
guided assembly [48]. Given the known complexity and
extensive alternative splicing of the TP63 gene we ana-
lyzed all RNA-Seq datasets using two pipelines, imple-
menting different transcript reconstruction methods and
annotation files (see Methods).
We ran the first analysis pipeline with the goal to
examine the six major p63 isoforms that are annotated
and well-defined in the literature (TAp63α, β, and γ,
ΔNp63α, β, and γ) as well as to detect novel transcripts.
We found that the longest C-terminal α variant was the
predominant isoform expressed across all p63 positive
cell-lines, irrespective of their source. Thus in all normal
and tumorigenic cell lines, in which the ΔNp63 tran-
scripts were detectable at appreciable levels, ΔNp63α
was several log fold higher than ΔNp63β and ΔNp63γ.
Of the two shorter isoforms, ΔNp63β displayed a relatively
widespread distribution as evident from its low to modest
expression (0–15 FPKM) in 11 out of 15 cell-lines, whereas
ΔNp63γ on the other hand was detected only at low
levels (<5 FPKM) in a small subset of HNSCC cell lines
(Additional file 3: Table S2). Interestingly ΔNp63β
levels remained consistent in differentiating keratinocytes
unlike the ΔNp63α isoform (Additional file 4: Figure S2).
The dynamic range of expression of the ΔNp63 iso-
forms suggests that there might exist a distinct func-
tional role for each isoform, especially the β isoform. In
most TAp63 expressing cell-lines, only the TAp63α iso-
form was detected at appreciable levels (Fig. 2). It is
important to note that in oocytes, where TAp63α is
highly expressed, it is thought to exist in an inactive
conformation due to complex domain-domain interac-
tions [49, 50]. Whether similar structural mechanism of
TAp63α inhibition also operates in BL cells is an inter-
esting question that needs to be addressed. Interest-
ingly, a novel p63 isoform, TAp63δ was identified in
the GUMBUS BL cell-line by the de novo method (as
Fig 2 Protein expression profiles of p63 isoforms. Western blot analysis of whole cell extracts demonstrates p63 expression using (a) a pan-p63
antibody (b) and an alpha specific antibody (H-129). TAp63 and ΔNp63 isoform specific expression is shown in panels (c) and (d) respectively. Blue
and red arrows mark the TAp63 and ΔNp63 protein bands, respectively. Beta-tubulin serves as a loading control. se: short exposure and
le:long exposure
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levels (data not shown). This is a shorter p63 isoform
that is generated by exon skipping in the 3’ end and
was only recently discovered [51].
Using a parallel approach we next examined the RNA-
Seq datasets using Analysis pipeline 2 (see Methods) and
employing a more comprehensive annotation library from
Ensembl (contains both known and predicted p63 iso-
forms). We found that the expression estimates for major
known p63 isoforms, i.e. ΔN (α, β and γ) and TAp63α
were robust and their relative distribution levels and pat-
terns were the same across the two methods. TAp63β and
TAp63γ were not detected whereas TAp63δ was con-
firmed to be expressed in GUMBUS cells (similar to Ana-
lysis pipeline 1) and additionally detected at very low
levels in FARAGE cells (Additional file 7: Figure S5). Inter-
estingly, this analysis revealed several additional ΔN C-
terminal variants, the most prominent being ΔNp63αΔ4, a
relatively close cousin of ΔNp63α. This transcript ispredicted to generate just four amino acids smaller protein
product compared to ΔNp63α and has been reported to
be expressed in mouse skin [21]. ΔNp63αΔ4 was present
at moderate to high levels in a number of ΔNp63 positive
cell-lines including keratinocytes, mammary epithelial and
HNSCC cells. On the other hand a few novel ΔN isoforms
such as ΔNp63ε and ENST00000434928 were detected
only in HMEC cells at low levels. Whether these isoforms
have a mammary epithelial cell specific function and/or
their detection is merely a consequence of the high se-
quencing depth (~250 million reads) of HMEC RNA-
Seq datasets needs to be further probed (Additional file 7:
Figure S5). It is possible that the full spectrum of C-
terminal variants for the TA isoform was not revealed by
both methods due to the fact that the TA promoter is less
active than the intronic ΔN promoter in most cell lines
and under physiological conditions.
Overall our analysis suggests that even though both
ΔN and TA transcripts undergo complex alternative
Sethi et al. BMC Genomics 2015, 16:1 Page 7 of 15
http://www.biomedcentral.com/1471-2164/16/1/splicing events, the major C-terminal variant expressed
in most cell lines is the α isoform and that minor tran-
scripts representing various splicing products can often
be unearthed using the power of deep sequencing and
sophisticated computational tools. We suspect though
that within the biological confines of any given cell, the
bulk of the p63 functional activity is driven by the major
α isoform, while the minor isoforms perhaps represent
the misfiring or over-activity of the splicing machinery.
This is in agreement with the emerging general view that
in a given condition, the transcriptome from protein
coding loci is dominated by one major transcript per
gene and often that same transcript is expressed across
many cell-types [52]. Further support for the biological
importance of the p63α isoform comes from recently
generated mouse knockouts, which demonstrates that
the C-terminus is vital to p63 function during embryonic
development [53]. Similar in vivo biochemical studies for
the p63β and γ as well as other minor isoforms will shed
light on their functional significance.
Detection of TAp63 and ΔNp63 proteins using a panel of
specific antibodies
While the RNA-Seq data provides a global first-hand
view of the repertoire of p63 transcripts in various cell
types, in most cases there have been no careful follow-
up studies to examine the corresponding protein products.
One major problem that has contributed to the dearth of
such protein-based studies is the lack of appropriate tools,
specifically of validated isoform-specific antibodies. This
has led to several unproven and likely erroneous assump-
tions in the field regarding the expression and stability of
the p63 isoforms. Indeed, one such often-repeated and
widely prevalent notion is that p63 isoforms may have inher-
ently different stability and posttranscriptional regulations
with TAp63 proteins being particularly susceptible to degrad-
ation and hence undetectable by western blot analysis.
Recently a panel of isoform-specific and pan anti-p63
antibodies were generated to address this concern [54].
Utilizing these antibodies we performed western blot ex-
periments on a selected panel of cells for which the
RNA-Seq data was available. As shown in Fig. 2, expres-
sion of various p63 protein isoforms was robustly detected
in several of the cell lines tested. This is in good agree-
ment with the corresponding mRNA level as determined
by RNA-Seq analysis. Strong expression of ΔNp63 was ob-
served in NHEK and HMEC cells as well as two represen-
tative SCC cell lines, UM-SCC-29 and UM-SCC-103. The
expected size of ~80 kD corresponded to the ΔNp63α iso-
form. In contrast, a higher migrating band of ~85-90 kD
was observed in BL2, RAJI and GM1278 cells which rep-
resent TAp63α. Western blotting with a commercial anti-
p63 antibody, H-129, which specifically recognizes the α
isoforms, confirmed this distinct and non-overlappingexpression pattern of the α isoform of ΔNp63 and TAp63
in these cells. Furthermore it was also apparent that the
expression of TAp63 in lymphoblast cell lines was consid-
erably lower than the abundant levels of ΔNp63 proteins
in epithelial cells, as evident by data from a longer expos-
ure (see Fig. 2a and b lower panels). Next we utilized TA
and ΔN-specific antibodies that have been well character-
ized in terms of their efficacy and specificity [54]. As
shown in Fig. 2c, anti-TAp63 antibodies detected a strong
band in five representative lymphoma cell lines with abso-
lutely no detectable expression in epithelial cells. This ex-
periment also revealed that the exquisite sensitivity of the
monoclonal antibodies makes it feasible to detect low
levels of TAp63 proteins even in cell lines that express
very low mRNA levels (<1 FPKM in GM12878 for e.g.). In
contrast, a band corresponding to ΔNp63α was clearly evi-
dent with anti-ΔNp63 antibodies in the representative epi-
thelial cells with the highest expression levels in NHEK
and SCC cells (Fig. 2d). It is also important to note that
under these western blot conditions, we could not detect
the less abundant isoforms of p63, such as β and γ - this
observation is in good agreement with the analysis of the
RNA-Seq data.
Expression pattern of p63 family members
The availability of the RNA-Seq data allowed us to
examine another important facet of p63 biology that is
important but not as well appreciated. Given the struc-
tural similarities between p63, p53 and p73 [55], their
DNA-binding affinity towards similar DNA sequences
and the proclivity to heterodimerize, it is likely that the
biological activity of p63 in a specific cell type will be
greatly influenced by the presence or absence of the
other two family members. Hence it is important to
examine the relative expression levels of p53 and p73 in
relation to ΔNp63 and TAp63. Of these two family
members, p73 was the least abundant and showed negli-
gible to low expression (<5 FPKM) across all of the 40
cell-types (Additional file 8: Figure S6). This is an ex-
pected finding, as p73 is important in neuronal develop-
ment [56, 57] and neural cell-types were not represented
in our dataset. In contrast p53 was moderately expressed
across most of the cell-types. Interestingly, p53 mRNA
levels were preferentially higher in breast adenocarcin-
omas (no expression of p63) and in NonHodgkin’s lymph-
omas (TAp63 expressing cell-lines) (Additional file 8:
Figure S6). At this stage, it is difficult to ascertain if there
is any significance to this finding. Another caveat to this
interesting p53/TAp63 correlation is the fact that the p53
status is quite varied across the different cell-types ranging
from wild-type, mutant to null. As expected, most of the
cancer cell-lines contained a missense or small frameshift
mutation in p53 (Additional file 1: Table S1). Since mutant
p53 can form heterotetramers with p63 and studies have
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uted in part to its interaction with p63 [58], the overall bio-
chemical attributes of p63 are likely to be influenced by the
p53 expression and mutation status in a specific cell type.
Meta-analysis of RNA-Seq expression data reveals
transcriptional co-regulators of p63
Cooperative interactions between TFs constitute an im-
portant and indispensable regulatory force that drives
tissue-specific gene expression programs. Hence, master
regulatory factors such as p63 that play crucial roles in
developmental and cell fate decisions are likely to be as-
sociated with an expansive repertoire of TFs. Presum-
ably, these p63-linked TFs act in a concerted fashion to
modulate the p63 biological output. One obvious corol-
lary to this idea is the possibility that such co-regulators
within the p63 network are likely to exhibit similar pat-
terns of expression across different cell types. To this
end, we examined expression datasets detailing the rela-
tive abundance of a large number of human TFs across
40 normal and cancer cell types. Given the distinct dif-
ferences in expression patterns of ΔN and TA, we incor-
porated transcript-specific data information for p63
isoforms in our analysis of the expression dataset. The
dataset was also filtered to remove both highly expressed
ubiquitous TFs and those with less abundant transcripts
(<5 FPKM in at least 1 cell-type). As ΔNp63γ and
TAp63 (β, γ) isoforms are expressed at low levels in
most of the human cells, they were not represented in
this analysis. Unsupervised hierarchical clustering across
both genes (867 differentially expressed TFs) and experi-
ments (52 RNA-Seq data sets) revealed quite interesting
expression patterns (Fig. 3a). Interestingly, cell-lines ap-
peared to cluster according to the germ layer of origin
and their physiological functions, irrespective of the
karyotype (normal vs. cancer). Replicates (as represented
by MCF7_rep1, MCF7_rep2) and cell-lines that were
from identical sources (such as NHEK, DK0) usually
clustered together, further ensuring that the method was
unbiased to data originating from different sources
(Additional file 9: Figure S7).
The dendrogram of the 867 differentially expressed
TFs revealed those that are most closely associated (at
correlation > = 0.6) with ΔNp63 and TAp63 based on
their expression pattern. As shown in Fig. 3, ΔNp63 and
TA clustered with distinct families of TFs. Importantly, as
revealed by this clustering analysis, many of the likely tran-
scriptional co-regulators of ΔNp63; TFAP2A, TFAP2C,
NOTCH3 and DLX3 (Fig. 3b) are known and established
players in the p63-related transcriptional circuitry and/or
biological activity in skin keratinocytes [17, 59–61]. Similar
results were also obtained from a recent study, which
showed AP2 as a likely transcriptional co-regulator of p63
based on TF motif enrichment and overlapping in-vivobinding profiles at p63 target sites in NHEK [59, 62]. On
the other hand, our analysis unearthed several novel players
including members of the IRX family, SOX15 and CITED4
for which there is no published link with p63 (Fig. 3b). As
expected from the virtually non-overlapping expression
pattern of the two major p63 isoforms, TAp63 clustered
with a very different group of TFs including LEF1, KLF15,
IRF8, RUNX3–interestingly some of these have been shown
to be associated with the p63 network and/or play a role in
B-lymphomas [63–65] (Fig. 3c).
In order to gain a deeper understanding of the rela-
tionships between ΔNp63 and TAp63 and the transcrip-
tional co-regulators that are likely to be biologically
relevant, we used Ingenuity Pathway Analysis (IPA) to
generate network maps (Fig. 4a and b). IPA primarily
uses experimental evidence as documented in the litera-
ture to define the pathway (shown by black lines) be-
tween two molecules. The notification next to the
relationship indicates the type of evidence that is de-
scribed in the literature (PP: Protein-Protein interaction,
A: Activation, I: Inhibition, T: Transcription, E: Expres-
sion, PD: Protein-DNA interaction). We overlaid the
maps with Functions and Disease data from IPA that
uses Gene Set Enrichment Analysis (GSEA) to find the
significant biological functions regulated by a group of
factors. Most of the likely transcriptional co-regulators
(green molecules) that clustered with ΔNp63 were deemed
to be linked within a ΔNp63 specific network, and import-
antly are involved in biological functions that include hair
and skin development and function (p value: 5.46E-14–
5.56E-6) (molecules with blue boundaries) (Fig. 4a,
Additional file 10: Table S3). Based on this analysis we
postulate that other novel TFs that have similar expres-
sion pattern to ΔNp63 (such as IRX family members
and SOX15) are likely to be an integral part of the p63
transcriptional network with a hitherto undiscovered
functional role in epithelial biology. Interestingly by
overlaying the ΔNp63 network with p63 ChIP-Seq data
(red arrows) from primary human keratinocytes [66],
we found that 8 out of the 15 predicted transcriptional
co-regulators are also direct targets of p63 (Fig. 4a).
This strongly raises the possibility that ΔNp63 is posi-
tioned in a central hub in the transcriptional circuitry
of many human cells where it directs gene expression
in a coordinated fashion with other TFs.
Similar IPA analysis elucidated the TAp63 centric net-
work and unearthed interesting relationships between
TAp63 and its predicted co-regulators (blue mole-
cules) in human cells. Many of these factors (12 out
of 21) are thought to be involved in a distinct bio-
logical function, that of lymphoid tissue structure and
development (p value: 5.17E-20–4.75E-5) (molecules
marked with blue boundaries) (Fig. 4b). Indeed, aberrant
expression and activity of TAp63 [67] together with some
Fig 3 Transcription Factors predicted to coordinate with ΔNp63 and TAp63 based on expression profiles (a) Heatmap depicts hierarchical
clustering of fold change in expression (over median) of 867 TFs across 40 cell-types (54 experiments). Trimmed dendrogram (correlation > = 0.6)
highlights the transcriptional regulators with similar expression pattern to (b) ΔNp63 and (c) TAp63, across a subset of cell-lines (depicted by
yellow dotted rectangle). The specific p63 isoforms are shown in red
Sethi et al. BMC Genomics 2015, 16:1 Page 9 of 15
http://www.biomedcentral.com/1471-2164/16/1/of these co-expressing TFs such as LEF1, BCL1A, RUNX3,
IRF8, have been linked to lymphomas [64, 68, 69]. Based
on this expression-based data, it is tempting to speculate
that the TAp63 network might constitute an important
regulatory module in lymphomas. Whether like ΔNp63,
TAp63 also directly regulates many of the co-expressed
TFs will necessitate future studies such as ChIP-seq with
anti-TAp63 antibodies in TAp63-enriched lymphoma cell
lines such as BL2 and BL30.
Expression pattern of p63 isoforms in human tissues and
organs
Thus far all of our analysis was based on RNA-Seq ex-
pression data from cell-lines, which may not reflect thephysiological state of human tissues. In order to deter-
mine whether the cell culture based results were indica-
tive of p63 expression in vivo, we next examined the
RNA-Seq data and Cap Analysis of Gene Expression
(CAGE) datasets that have been recently generated by
the Human Protein Atlas Project [70] and the FANTOM
Consortium [71], respectively. The CAGE information,
which provides a readout of the human transcription
start site activity, allowed us to specifically examine the
ΔNp63 and TAp63 promoter in a number of human tis-
sues and organs. On the other hand, the RNA-Seq data
were pre-processed that provided overall p63 expression
levels without any isoform-specific details. The RNA-Seq
and CAGE data sets showed a congruous pattern and
Fig 4 (See legend on next page.)
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(See figure on previous page.)
Fig 4 ΔNp63 and TAp63 TF networks. (a) Interaction Network for ΔNp63. Green molecules denote predicted co-regulators. Red arrows represent
TFs that are likely direct targets of p63 as determined by overlay with ChIP-Seq information. Molecules with blue boundaries are those involved
in Hair and Skin development and function. (b) Interaction Network of TAp63. Molecules denoted in blue are the predicted co-regulators.
Molecules with green boundaries are involved in lymphoid tissue structure and development. The interaction networks (black lines connecting
molecules) were generated by QIAGEN’s Ingenuity Pathway Analysis. The specific type of evidence in literature is denoted by–PP: Protein-Protein
interaction, A: Activation, I: Inhibition, T: Transcription, E: Expression, PD: Protein-DNA interaction
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http://www.biomedcentral.com/1471-2164/16/1/reaffirmed the notion that similar to what was observed
for cell lines, ΔNp63 is the predominant isoform in human
tissues and organs, particularly in those that are epithelial-
enriched. Indeed ΔNp63 was highly expressed in skin,
esophagus, prostate and other epithelial-enriched tissues,
whereas TAp63 was weakly expressed or absent in most of
the examined tissues with low expression in a few tissues
and cell types such as adipocytes (Fig. 5a).
The availability of human tissue RNA-Seq datasets also
allowed us to perform unsupervised hierarchical cluster-
ing using Pearson correlation distance metric similar, to
what was done with the cell-line datasets (Fig. 5b). The set
of TFs that cluster with p63 in human tissues (Fig. 5c)
match well with the predicted transcriptional co-regulators
of ΔNp63 based on cluster analysis of the cell-line expres-
sion datasets (see Fig. 3b). Thus a number of TFs, in par-
ticular AP2 and IRX family members and SOX15 have a
similar expression pattern to p63 (ΔNp63) across both tis-
sues and cell-lines. It is also important to note that a subset
of these p63 co-factors were also uncovered in a similar
clustering analysis of mouse tissues [21] suggesting that
there exists an evolutionarily conserved transcriptional net-
work that is anchored by ΔNp63. In contrast, we did not
find any TAp63 associated TFs that clustered with p63 in
the tissue expression dataset. This is an expected finding
because of low TAp63 mRNA levels across the spectrum of
the human tissues. These findings collectively reinforce
the prevailing notion that ΔNp63 is the predominantly ex-
pressing isoform and hence functionally relevant in most
human tissues and organs, as is the well-documented case
in mouse.Conclusions
Our comprehensive analysis of the isoform diversity and
dynamic expression pattern of p63 in various human cell
lines and tissues as described in this report, highlights
the power of emerging genomics tools to generate
meaningful data and testable hypotheses. We show that
the two major isoforms of p63, ΔNp63 and TAp63 have
their own distinct expression profile, which is like to dic-
tate their unique biological activities and functional part-
nerships. In future, in depth examination of additional
human cell lines and tissues, representing a wide range
of physiological and pathological states will surely offernew insights into the p63 family of factors and their
broad transcriptional network.Materials and methods
Cell lines
Human HNSCC cell-lines SCC15, SCC351, SCC4, SCC71,
UM-SCC-29 and UM-SCC-103 were grown in high glu-
cose (25 mM) DMEM media containing 1 % penicillin/
Streptomycin, 4 mM L-Glutamine and 10 % fetal bovine
serum. For UM-SCC-29 and UM-SCC-103 (obtained from
University of Michigan [72, 73]) the media was also sup-
plemented with 1 % non-essential amino acids. Lymph-
oma cell lines BL2, BL30, Raji and Daudi were grown in
RPMI 1640 media containing 10 % fetal bovine serum, 1 %
penicillin/streptomycin and 1 % GlutaMAX. Breast cancer
cell lines MCF7 was grown in high glucose (25 mM)
DMEM media containing 1 % penicillin/Streptomycin and
10 % fetal bovine serum, whereas T47D cells were grown
in RPMI media supplemented with 1 % penicillin/Strepto-
mycin and 10 % fetal bovine serum. NHEK and HMEC
cells were obtained from Lonza and grown in KGM and
MEGM growth medium respectively. GM12878 cells were
obtained from Coriell Institute for Medical Research
and grown in RPMI 1640 media containing 2 mM L-
glutamine, 10 % fetal bovine serum and 1 % penicillin/
streptomycin.RNA extraction and quantitative Reverse-Transcriptase
Polymerase Chain Reaction (qRT-PCR)
Total RNA was collected and purified, using the Direct-zol
RNA Purification Kit (Zymo Research), from the following
cell lines: BL30, RAJI, GM12878, NHEK, T47D, MCF7,
UM-SCC-29, UM-SCC-103. Equal amounts of RNA
(~1 μg) were reverse-transcribed to cDNA using the
QuantiTect Reverse Transcription Kit (Qiagen). qRT-
PCR assays were performed on the CFX96 Touch Real-
Time PCR Detection System (Bio-Rad) using the iQ
SYBR Green Supermix (Bio-Rad). Differential isoform
specific gene expression was determined using the
ΔΔCT method, using Glyceraldehyde 3-Phosphate De-
hydrogenase (GAPDH) as an internal control. The ex-
pression levels are reported in terms of fold change
relative to a specific cell type with the lowest levels of
the two p63 isoform as determined by RNA-Seq data
Fig 5 Predicted transcriptional co-regulators of ΔNp63 in human tissues and organs (a) Heatmap depicting transcript abundances of p63 across
major human tissues and organs using CAGE-Seq and RNA-Seq (as obtained from the FANTOM database and the Human Protein Atlas). TPM:
transcripts per million; FPKM: fragments per kilobase of transcript per million. (b) Hierarchical clustering of fold change in RNA-Seq expression
(over median) of 867 TFs (rows) across 27 major tissues and organs, (c) Close-up shows a trimmed dendrogram (correlation > = 0.65) depicting
the TFs with most similar expression pattern to p63 (shown in red)
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primers were used: TAp63 (Forward: CCCAGAGCAC
ACAGACAAATG Reverse: GCGGATACAGTCCATG
CTAATC), ΔNp63 (Forward: GAGCCAGAAGAAAGG
ACAGCAG Reverse: GAATCTGCTGGTCCATGCTG
TTC), GAPDH (Forward: AGCCACATCGCTCAGA
CA Reverse: GCCCAATACGACCAAATCC).
RNA-Seq analysis
Total RNA was extracted using the Direct-zol RNA Mini-
Prep kit (Zymo Research), from 6 HNSCC cell-lines:SCC15, SCC351, SCC4, SCC71, UM-SCC-29 and UM-
SCC-103. For each RNA sample, cDNA libraries were pre-
pared using the TrueSeq RNA Sample Preparation Kit
(Illumina). The samples were then 50 bp single-end se-
quenced at ~ 25 million reads per sample on an Illumina
HiSeq 2500. The RNA-Seq data has been deposited in
GEO under the accession number GSE68872.
Analysis pipeline 1: TopHat, Cufflinks
Raw sequencing reads from the eight HNSCC RNA-Seq
experiments (RNA-Seq for SCC15 and SCC351 cell-lines
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http://www.biomedcentral.com/1471-2164/16/1/were done in replicates) and 46 publicly available data-
sets (22 cell-lines: 1 replicate, 12 cell-lines: 2 replicates)
were mapped to the Homo sapiens genome (hg19 build)
using TopHat (v2.0.7), with default parameters and Illumi-
na’s iGenomes transcript annotation file ‘genes.gtf ’ (from
RefSeq; hg19) available at http://support.illumina.com/
sequencing/sequencing_software/igenome.ilmn. Gene iso-
form level transcript abundances were quantified as
Fragments Per Kilobase of transcript per Million mapped
reads (FPKM) using Cufflinks (v2.1.1) [34].
Analysis pipeline 2: Bowtie, RSEM
Raw sequencing reads from the 54 experimental data sets
were mapped to the Homo sapiens genome (hg19 build)
using RSEM’s (v1.2.19) implementation of Bowtie (v1.1.1)
[74] alignment program with poly-A option on and Illumi-
na’s iGenomes transcript annotation file ‘genes.gtf ’ (from
Ensembl; GRCh37) (Script: rsem-prepare-reference). Gene
and isoform level abundances were quantified as FPKM
values using RSEM (Script: rsem-calculate-expression) [35].
Clustering and network analysis
Transcript-probe level FPKM data as processed by Analysis
Pipeline 1 from 40 cell-lines (54 experimental data points)
was filtered for 1094 transcription factors (TFs) in H.sapi-
ens (as annotated by QIAGEN’s Ingenuity Pathway Ana-
lysis: IPA, http://www.qiagen.com/ingenuity). We then
performed a summation of expression for all possible tran-
scripts of a TF to generate gene-probe level expression data.
This was done for all 1093 TFs (excluding p63) resulting in
a 1099 × 54 data matrix. This RNA-Seq expression matrix
was then log transformed (log2 [FPKM+ 1]). To reduce
noise, we filtered the matrix to keep only significantly
expressed (>5 FPKM in at least one experiment) and differ-
entially expressed TFs (>2 fold difference between mini-
mum and maximum expression values across all cell-lines).
This final dataset (867 × 54) was then clustered using un-
supervised hierarchical clustering based on average linkage
and Pearson correlation distance metric as implemented in
Cluster 3.0 software package [75]. The genes were centered
on their median expression value across all experiments,
prior to visualization of the clustering using Treeview [76].
ΔNp63 and TAp6-specific networks were generated using
Ingenuity Pathway Analysis (IPA). The path explorer tool
built the shortest relationship between ΔNp63 and TAp63
isoforms and their predicted transcriptional co-regulators.
These relationships were then manually filtered to remove
paths arising from pan-isoform studies, where no isoform
specific function was provided. The networks were then
overlaid with functions and disease data.
Western blot
Western blot analysis was performed as previously de-
scribed [77]. Primary antibodies were used at the followingdilutions: Pan-p63 (Nekulova et al. [54], 1:5000), H-129
(Santa Cruz, 1:5000), TAp63 (Nekulova et al. [54], 1:5000),
ΔNp63 (Nekulova et al. [54], 1:5000) and beta-Tubulin
(Sigma, 1:10,000).Additional files
Additional file 1: Table S1. Cell-line database. Columns A–E
characterize the 40 cell-types. Columns F–H provide information about
the number of replicates, type of sequencing (single vs. paired end) and
number of reads aligned. Column I give information about the p53 status
of each of the cell-types (if known), as documented in the UMD TP53
mutation database (http://p53.free.fr/Database/p53_database.html). The
PUBMED ID and reference for the studies that generated the RNA-Seq
data for each of the cell-types is shown in columns J and K, respectively.
(XLS 54 kb)
Additional file 2: Figure S1. Expression estimates of genes are consistent
across two independent analysis pipelines. RNA-Seq expression of 1094 TFs
across 54 experiments was calculated by two methods: Analysis Pipeline 1
(Tophat, Cufflinks) and Analysis Pipeline 2 (Bowtie, RSEM). (A) Notched
Box-plot depicting median correlation of 0.9 between RNA-Seq expression
datasets (expression estimates in FPKM for 1094 TFs X 54 cell-lines) from the
two methods. (B) Scatter plot with linear square fitted line showing high
correlation between the expression estimates from the two methods
(average across replicates), for 1094 TFs across individual representative
cell-lines. (PDF 176 kb)
Additional file 3: Table S2. Expression database. Column A contains
the names of the 1099 TFs in humans. Columns B–BC provide the
expression of the TFs in FPKM (fragments per kilobase of transcript per
million), as calculated by Analysis Pipeline 1, across the 40 cell-types
(52 experiments). (CSV 553 kb)
Additional file 4: Figure S2 qRT-PCR reveals distinct expression
patterns for TAp63 and ΔNp63. (A) Bar plot depicting normalized expression of
ΔNp63 (to GAPDH) in a representative set of cell-lines. Asterix indicates that
RAJI cell-line was used as reference control. (B) Bar plot depicting normalized
expression of T Ap63 (to GAPDH) in a representative set of cell-lines. Asterix
indicates that NHEK cell-line was used as reference control. (PDF 45 kb)
Additional file 5: Figure S3. ΔNp63α is the predominant isoform in
both proliferating and differentiating keratinocytes. Line chart depicting
expression of p63 isoforms in human keratinocytes at three time points
during differentiation: Day 0(DK0), Day3 (DK3) and Day 6(DK6). ΔNp63α
levels are attenuated during keratinocyte differentiation whereas TAp63
expression is not detectable at any time points under these conditions.
Also shown are expression pattern of differentiation markers, FLG and
EHF. FPKM: fragments per kilobase of transcript per million. (PDF 30 kb)
Additional file 6: Figure S4. Chromatin landscape at the TP63 gene
locus in NHEK, GM12878 and MCF cells. A snapshot from the UCSC genome
browser showing expression (RNA-Seq) and accessibility (DNase-Seq) at the
TP63 gene across three cell types: Normal Human Epidermal Keratinocytes
(NHEK), B-lymphoblastoid (GM12878) and Breast adenocarcinoma (MCF7)
cells. The dotted red boxes highlight the TA and ΔN promoters. (PDF 55 kb)
Additional file 7: Figure S5. p63 isoform expression as estimated by
Analysis Pipeline 2. Heatmap depicting the expression of p63 isoforms in
FPKM (fragments per kilobase of transcript per million), across representative
p63 expressing cell-lines. (PDF 44 kb)
Additional file 8: Figure S6. Expression pattern of P53/P63/P73 family.
Heatmap depicting the expression of p63 isoforms in relation to p53 and
p73, across 40 human cell-types. These are commonly used cell-lines
corresponding to all three germ layers and both normal and cancer
karyotypes. Expression is quantified in FPKM (fragments per kilobase of
transcript per million). (PDF 34 kb)
Additional file 9: Figure S7. Unsupervised Clustering of the human
cell-lines. The 40 cell-types (54 experiments) clustered using unsupervised
hierarchical clustering based on average linkage and Pearson correlation
distance metric. TAp63 expressing cell-lines are shown in green, ΔNp63
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http://www.biomedcentral.com/1471-2164/16/1/expressing cell-lines are shown in red. rep1: replicate 1, rep2: replicate 2.
(PDF 30 kb)
Additional file 10: Table S3. Biological functions enriched in ΔNp63 and
TAp63 networks by IPA. Column A provides the diseases/biological functions,
column B provides the p value of enrichment for the functions (calculated by
Fisher’s exact test) and columns C and D provide the number and details of
molecules that are involved in that function.
(CSV 2 kb)
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